Hematology Denial Patterns
Hematology practices experience denial rates of 6% to 10%, but the financial impact per denial is substantially higher than most specialties because individual treatment claims routinely exceed $5,000 and can reach $50,000+ for high-cost biologic therapies. A single denied chemotherapy claim may represent more lost revenue than an entire month of denied E/M claims in a primary care practice. The stakes are high, and the denial prevention strategy must be equally robust. The two highest-risk denial categories are drug authorization failures and administration coding errors, which together account for 60% to 70% of hematology denial dollars.
Denial Reason 1: Drug Authorization Failure (CARC 197)
CARC 197 (prior authorization required) denials on chemotherapy claims are the most costly denials in hematology. A denied cycle of chemotherapy can represent $5,000 to $50,000 in lost revenue depending on the drug. Authorization failures occur when: the authorization was not obtained before treatment, the authorization expired between cycles, the drug or dose on the claim does not match the authorization, or the number of authorized cycles has been exceeded. Build a treatment authorization tracker that monitors every patient active treatment plan, authorization number, authorized cycles, and expiration date. Verify authorization status before every treatment session, not just at the start of the regimen.
Denial Reason 2: Administration Code Hierarchy Errors (CARC 97)
CARC 97 (payment adjusted per bundling rules) appears when administration codes are assigned out of hierarchy or when the documentation does not support the time-based codes billed. Common errors: billing 96413 (first hour chemotherapy infusion) for a drug that was pushed IV (should be 96409), billing multiple first-hour codes when only one initial code is allowed per session, billing hydration that ran concurrently with chemotherapy (hydration must run independently for 31+ minutes to be separately billable), and billing add-on codes without the required primary code. Train billing staff on the administration hierarchy and conduct quarterly audits of infusion billing to catch systematic errors.
Denial Reason 3: J-Code Quantity Disputes (CARC 45)
CARC 45 (charge exceeds fee schedule) and related denials appear when the payer disputes the number of drug units billed. If the payer records show a standard dose of 500 mg but the claim bills for 600 mg (due to a weight-based dose calculation for a heavier patient), the payer may deny the excess units. Support dose calculations with the patient weight, the dosing protocol (mg/kg or mg/m2), and the calculated dose documented in the treatment record. Also verify that the J-code used matches the specific drug product administered. Biosimilar products have separate J-codes from reference biologics, and billing the wrong J-code triggers a denial.
Denial Reason 4: Medical Necessity for Off-Label Use (CARC 50)
Hematologists frequently use drugs for indications supported by the NCCN Compendium or clinical trial data but not specifically listed in the FDA-approved label. CARC 50 (not medically necessary) denials for off-label drug use require appeals with clinical documentation supporting the use. Medicare covers drugs listed in approved compendia (NCCN, AHFS, Elsevier Gold Standard). Commercial payers vary in their coverage of off-label use. When using a drug off-label, document the clinical rationale, the compendium reference supporting the use, and the patient-specific factors that make this treatment appropriate. Include this documentation in the prior authorization request.
Denial Reason 5: Timely Filing for High-Cost Claims
Timely filing denials on hematology claims are especially costly because the high claim values cannot be recovered once the filing deadline passes. Most payers have 90 to 180 day filing limits from the date of service. Drug claims that are held pending authorization resolution, pathology results, or dose confirmation may miss the filing deadline if not monitored. Track every high-value claim (above $1,000) individually and set filing deadline alerts at 60 days post-service. If a claim is held for any reason beyond 60 days, escalate it to a supervisor for immediate resolution.
Preventing Hematology Denials
Four systems prevent the majority of hematology denials: a treatment authorization tracker verified before every session, infusion documentation templates with required start/stop time fields and drug-to-code mapping, a J-code unit calculator that computes billing units from prescribed doses automatically, and a timely filing tracker for all claims above $1,000. These four systems address the highest-risk denial categories and protect the most vulnerable revenue. Review denial trends monthly by drug and by CARC code to identify emerging patterns.